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Abstract
Background—Assays that detect HIV antigen (Ag) and antibody (Ab) can be used to screen for 
HIV infection.
Objectives—To compare the performance of the BioPlex 2200 HIV Ag-Ab assay and two other 
Ag/Ab combination assays for detection of acute HIV infection.
Study Design—Samples were obtained from 24 individuals (18 from the US, 6 from South 
Africa); these individuals were classified as having acute infection based on the following criteria: 
positive qualitative RNA assay; two negative rapid tests; negative discriminatory test. The samples 
were tested with the BioPlex assay, the ARCHITECT HIV Ag/Ab Combo test, the Bio-Rad GS 
HIV Combo Ag-Ab EIA test, and a viral load assay.
Results—Twelve (50.0%) of 24 samples had RNA detected only (>40 to 13,476 copies/mL). Ten 
(43.5%) samples had reactive results with all three Ag/Ab assays, one sample was reactive with 
the ARCHITECT and Bio-Rad assays, and one sample was reactive with the Bio-Rad and BioPlex 
assays. The 11 samples that were reactive with the BioPlex assay had viral loads from 83,010 to 
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>750,000 copies/mL; 9/11 samples were classified as Ag positive/Ab negative by the BioPlex 
assay.
Conclusions—Detection of acute HIV infection was similar for the BioPlex assay and two other 
Ag/Ab assays. All three tests were less sensitive than a qualitative RNA assay and only detected 
HIV Ag when the viral load was high. The BioPlex assay detected acute infection in about half of 
the cases, and identified most of those infections as Ag positive/Ab negative.
Keywords
HIV; acute; Ag/Ab assay; BioPlex
BACKGROUND
Screening for HIV infection can be performed with assays that detect HIV antibody (Ab) 
only (3rd generation assays) or with combination assays that detect HIV antigen (Ag) and 
Ab [1, 2]. The ability to detect HIV Ag in addition to Ab can shorten the window period for 
detection of HIV infection [3, 4]. Assays that provide one test result for Ag and/or Ab are 
often referred to as 4th generation assays. These assays can detect acute (Ag-positive/Ab-
negative) HIV infections [5]. Some Ag/Ab assays provide separate test results for HIV Ag 
and Ab [3]; these assays have the potential to identify acute infections.
In 2015, the United States (US) Food and Drug Administration (FDA) approved use of the 
BioPlex 2200 HIV Ag-Ab (BioPlex) assay for HIV testing [6]. BioPlex is an automated, 
multiplex flow immunoassay that provides separate results for detection of HIV-1 p24 Ag, 
HIV-1 Ab (groups M and O), and HIV-2 Ab [7]. Previous reports indicate that the overall 
sensitivity and specificity of the BioPlex assay are similar to other Ag/Ab assays [8–10]. 
Those studies included relatively few acute HIV infection samples (range: 4-13 samples) [8–
10]. This study evaluated the ability of the BioPlex assay to detect and identify acute 
infections.
OBJECTIVES
To evaluate the performance of the BioPlex assay for detection and identification of acute 
HIV infection.
STUDY DESIGN
Retrospective testing was performed using pre-seroconversion plasma samples from 
participants in the HIVNET 015 (EXPLORE) study (samples from the US) [11, 12] and the 
HPTN 067 (ADAPT) study (US and South Africa). HIVNET 015 was a vaccine 
preparedness study. HPTN 067 evaluated use of tenofovir disoproxil fumarate/emtricitabine 
(TDF/FTC) for pre-exposure prophylaxis (PrEP) [13, 14]. Samples were initially tested with 
two HIV rapid tests (Oraquick Advance Rapid HIV-1/2 Antibody Test, Orasure 
Technologies, Bethlehem, PA; Uni-Gold Recombigen HIV-1/2, Trinity Biotech PLC, Bray, 
Ireland), an HIV discriminatory test (Geenius HIV 1/2 Supplemental Assay, Bio-Rad 
Laboratories, Redmond, WA), and a qualitative HIV RNA assay (Aptima HIV-1 RNA 
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Qualitative Assay, Hologic Gen-Probe, San Diego, CA); limit of detection: 30 copies/mL). 
Acute infection was defined by detection of HIV RNA in samples that had two non-reactive 
rapid tests and a negative discriminatory test. Samples classified as acute infections were 
tested with three Ag/Ab assays: the ARCHITECT HIV Ag/Ab Combo test (ARCHITECT 
Combo; Abbott Laboratories, Abbott Park, IL), the GS HIV Combo Ag-Ab EIA test (Bio-
Rad Combo), and the BioPlex 2200 HIV Ag-Ab assay (BioPlex; Bio-Rad Laboratories). 
HIV viral load testing was performed using RealTime HIV-1 Viral Load assay (Abbott 
Molecular, Des Plaines, IL); samples with limited plasma volume were tested with a 
validated dilution version of this assay with a limit of detection of 400 copies/mL HIV RNA. 
The Ag/Ab assays determine reactivity based on a signal-to-cutoff ratio (S/CO, 
ARCHITECT Combo and Bio-Rad Combo) or Index Value (BioPlex). The BioPlex package 
insert indicates that index values are not correlated with HIV viral load [7].
RESULTS
Samples were analyzed from 24 individuals with acute infection (US [n=18], South Africa 
[n=6]). All 24 samples had non-reactive HIV rapid tests, a negative HIV discriminatory test, 
and a positive qualitative HIV RNA test (Table). The samples were also tested with three 
Ag/Ab assays (ARCHITECT Combo, Bio-Rad Combo, BioPlex) and a viral load assay. 
Twelve (50.0%) samples had non-reactive results with all three Ag/Ab assays. Three of the 
12 samples were positive with the qualitative HIV RNA assay only (viral load <400 copies/
mL); the remaining nine were positive with both the qualitative HIV RNA assay and a viral 
load assay (median viral load: 2,917 copies/mL; range: 400 to 13,476).
The remaining 12 (50.0%) samples were positive with both HIV RNA assays and had 
reactive results with at least two of the three Ag/Ab assays. This included: 10 that were 
reactive with all three Ag/Ab assays (median viral load: >750,000; range: 176,185 to 
>750,000), one that was reactive with the Abbott Combo and Bio-Rad Combo assays only 
(viral load: 125,848 copies/mL), and one that was reactive with the Bio-Rad Combo assay 
and the BioPlex assay only (viral load: 83,010 copies/mL). Among the 11 (45.8%) samples 
that had a reactive BioPlex result, two had both Ag and Ab detected (viral load: >750,000 
copies/mL) and nine had Ag detected only (median viral load: 662,217 copies/mL; range: 
83,010 to >750,000). For all three assays, there was no correlation between the S/CO or 
Index Values and viral load in this set of acute infection samples (Supplementary Figure).
CONCLUSIONS
In this study, detection of acute HIV infection was similar for the BioPlex, ARCHITECT 
Combo, and Bio-Rad Combo assays. The BioPlex assay was reactive for 11 (45.8%) of 24 
acute infection samples, and identified 9 (39%) of the samples as Ag positive/Ab negative. 
All three Ag/Ab assays were less sensitive than a qualitative HIV RNA assay, and only 
detected HIV Ag when the HIV viral load was high (samples reactive with all three assays 
had viral loads >170,000 copies/mL). The US Centers for Disease Control recommends use 
of an Ag/Ab assay for HIV screening. If the Ag/Ab assay is non-reactive, no further testing 
is needed [2]. This algorithm would have missed about half of the acute infections in this 
study. There is currently only one other FDA-approved HIV Ag/Ab assay that reports 
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separate results for Ag and Ab detection (the Alere Determine HIV-1/2 Combo rapid test, 
Alere, Scarborough, ME) [6]. That test is more sensitive than 3rd generation screening 
assays for detecting acute infection, but less sensitive than laboratory-based Ag/Ab assays 
[15, 16]. HIV RNA testing is currently the most sensitive method for detection of acute HIV 
infection. However, use of individual HIV RNA assays to screen for acute infections is 
costly. Pooled HIV RNA assays offer a less costly method for detecting acute HIV infection, 
but are less sensitive, more complex, and more labor-intensive than individual HIV RNA 
assays [17].
Previous studies have shown that HIV subtype may affect the performance of some HIV 
screening assays [18, 19]. A limitation of the study was that the sample set included only six 
acute infection samples from subtype C endemic areas. The sample set also included only 
two samples with HIV viral loads between 10,000 and 100,000 copies/mL. Analysis of a 
larger set of acute infection samples in this viral load range is needed to determine the 
amount of virus needed for detection of acute infection with each assay.
This study included eight samples from a PrEP trial [13, 14]. Only three of the eight 
infections were detected by Ag/Ab tests (Cases 2, 5, and 12). Four (50.0%) of the eight 
samples had viral loads ≤400 copies/mL, compared to none of the 16 samples from the 
HIVNET 015 study, which was performed before PrEP was in use. Two of the four 
participants with low viral loads were infected at study enrollment (prior to PrEP 
administration); one was infected prior to study randomization after receiving once-weekly, 
directly-observed TDF/FTC; and one was randomized to an event-driven PrEP regimen, but 
had no study drug detected in the months preceding the acute infection visit. Therefore, it is 
unlikely that PrEP use was the cause of viral suppression in these cases.
In this study, the BioPlex assay, ARCHITECT Combo assay, and Bio-Rad Combo assay 
each detected about one half of the acute infections. The BioPlex assay identified 9 (39%) of 
the 23 samples as Ag positive/Ab negative infections. Additional information is needed to 
determine whether detection of Ab by the BioPlex assay in the two remaining samples 
reflects more sensitive detection of Ab by this assay, or a false positive Ab result.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• The BioPlex assay and two other Ag/Ab assays had similar sensitivity for 
detecting acute infection.
• HIV RNA assays were more sensitive than Ag/Ab assays for detecting acute 
infection.
• HIV Ag was only detected by the BioPlex assay when the HIV viral load was 
high.
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